- Home
- DINO vs QGEN Comparison
DINO vs QGEN Comparison
Compare DINO & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DINO | QGEN |
|---|---|---|
| Founded | 1947 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.2B |
| IPO Year | 2022 | 1998 |
Fundamental Metrics
Financial Performance| Metric | DINO | QGEN |
|---|---|---|
| Price | $63.71 | $39.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $59.45 | $51.30 |
| AVG Volume (30 Days) | ★ 3.1M | 1.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 3.16% | ★ 6.07% |
| EPS Growth | ★ 238.46 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.48 | $8.18 |
| Revenue Next Year | N/A | $5.66 |
| P/E Ratio | ★ $20.49 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.66 | $38.13 |
| 52 Week High | $63.63 | $57.82 |
Technical Indicators
Market Signals| Indicator | DINO | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 67.49 | 26.41 |
| Support Level | $47.04 | N/A |
| Resistance Level | N/A | $49.11 |
| Average True Range (ATR) | 2.06 | 0.96 |
| MACD | 0.55 | -0.03 |
| Stochastic Oscillator | 94.06 | 3.11 |
Price Performance
Historical ComparisonAbout DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).